Novo Nordisk, Wegovy
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback